Last reviewed · How we verify

NCT06338670: RECONNECT

Clinical Performance of the Osia 3 Sound Processor Compared With the Osia 2 Sound Processor in Adult Osia Implant Users

Completed NA Last updated 21 January 2026
What this trial tests

NA trial testing Cochlear Osia 3 Sound Processor in Hearing Loss, Mixed Conductive-Sensorineural in 12 participants. Completed in 23 July 2025.

Timeline
4 July 2024
Primary endpoint
23 July 2025
23 July 2025

Quick facts

Lead sponsorCochlear
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment12
Start date4 July 2024
Primary completion23 July 2025
Estimated completion23 July 2025
Sites1 location across Australia

Drugs / interventions tested

Conditions studied

Sponsor

Cochlear — full company profile →

Who can join

18 and older, any sex, with Hearing Loss, Mixed Conductive-Sensorineural or Hearing Loss, Conductive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the clinical performance of the Osia 3 Sound Processor in comparison to the Osia 2 Sound Processor in adults with mixed or conductive hearing loss or single-sided deafness implanted with an Osia implant. Participants will attend four study visits, where they will complete various hearing assessments using the Osia sound processors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Cochlear trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06338670.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing